Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simsarian

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2008
Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week resultsG Giovannoni, O Barbarash, F Casset-Semanaz, et al.
Clinical Therapeutics|August 19, 2007
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosisGavin Giovannoni, Olga Barbarash, Florence Casset-Semanaz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 24, 2003
The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosisJ A Wilken, R Kane, C L Sullivan, et al.
Physical Review Letters|March 23, 2002
Photoassociation of sodium in a Bose-Einstein condensateC McKenzie, J Hecker Denschlag, H Häffner, et al.
Journal of Neurology|May 16, 2009
Factors that influence adherence with disease-modifying therapy in MSKatherine Treadaway, Gary Cutter, Amber Salter, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 30, 2008
Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week resultsG Giovannoni, O Barbarash, F Casset-Semanaz, et al.
Clinical Therapeutics|August 19, 2007
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosisGavin Giovannoni, Olga Barbarash, Florence Casset-Semanaz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 24, 2003
The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosisJ A Wilken, R Kane, C L Sullivan, et al.
Physical Review Letters|March 23, 2002
Photoassociation of sodium in a Bose-Einstein condensateC McKenzie, J Hecker Denschlag, H Häffner, et al.
Journal of Neurology|May 16, 2009
Factors that influence adherence with disease-modifying therapy in MSKatherine Treadaway, Gary Cutter, Amber Salter, et al.
Pageof 2